420 with CNW – Group Claims Federal Government Broke the Law in Cannabis Scheduling Evaluation

The Competitive Enterprises Institute, a libertarian think tank, has claimed in a formal filing that the federal government erred in the way it handled the scientific evaluation of cannabis’ therapeutic value, and the government must therefore take steps to fix the errors it made.

Their request for correction was sent to the Department of Health and Human Services (U.S. HHS). HHS had written to the DEA in 2015 and the DEA relied on that letter from HHS in determining that marijuana be classified as a Schedule 1 drug in the U.S.

According to CEI (Competitive Enterprises Institute), the letter sent by HHS lacked a very important element which is required by federal law. The federal Information Quality Act demands that such “highly influential scientific assessment” as the contents of the HHS letter to the DEA be subjected to a peer review evaluation before the information therein can be relied upon when making regulatory decisions.

No such peer review was conducted, and the CEI is demanding that HHS withdraws its letter to the Drug Enforcement Administration until the requisite peer review exercise has been done as stipulated in the law.

The DEA leaned heavily on the contents of the letter written by HHS to the effect that “marijuana has no recognized medical use in the U.S., has a high potential for abuse and doesn’t have an acceptable level of safety even when used under medical supervision.” Based on this information, the DEA rejected an application which had been made to have marijuana rescheduled in 2016.

In its letter to HHS, CEI points out that various medical associations and a huge fraction of the public in the U.S. have formed a largely different conclusion about marijuana. By law, HHS now has a maximum of 120 days within which to respond to the concerns raised by the Competitive Enterprises Institute.

Devin Watkins, an attorney for CEI, says that the federal government’s policy is likely to change if a reassessment of the matter is conducted. This is especially likely given that 33 states across the country have legalized marijuana for medical use.

The attorney added that the reassessment would be significant in ensuring that government agencies don’t brand uninformed opinions as scientific positions upon which public policies are made. Independent experts can shine a torch on the opinion of an agency and correct it if a mistake has been made.

Industry observers suspect that the entire cannabis industry, including players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Hemptown USA, are likely to follow keenly how HHS responds to the letter written by CEI.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments

CannabisNewsWire Editorial Coverage: Experiments with next-generation delivery systems appear certain to lead to better cannabis-based products.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has recently seen spectacular improvements in the effectiveness of cannabinoids thanks to its proprietary chemical delivery treatment. GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF), which has won widespread praise for its innovative medical work, has seen good trial results for a new treatment for seizures.  Tilray Inc. (NASDAQ: TLRY) is supporting studies into the uses of cannabinoids to treat behavioral problems and HIV. MariMed Inc. (OTCQB: MRMD) has set up a subsidiary focused on CBD, currently the highest-profile cannabinoid product. Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) has established a new research lab to develop…

Read More >>

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

420 with CNW – French Medical Marijuana Experiment Starting Soon After Enabling Law is Passed

On May 28 this year, the French Senate passed a bill paving the way for marijuana to start being used therapeutically in the country. The health ministry is yet to give its approval to this law, but once it does, an experiment lasting two years will be launched to analyze the effects of marijuana on pain relief.

Patient groups put the estimate of people who would be eligible to access marijuana for pain at about 300,000-1,000,000 people. A committee is evaluating the measures which have been designed to implement the medical cannabis experiment. This committee will release their findings on June 26.

The experiment is likely to get underway in a few weeks, but the biggest challenge which will be faced is how to set up a supply chain for the industry. Initially, medical cannabis will be imported from countries where it is legal and produced to internationally acceptable standards.

As medical cannabis is imported, locally licensed producers will be busy at work setting up cultivation facilities in greenhouses or highly controlled fields. The sunlight, humidity and temperature will all be closely monitored and controlled in this unconventional agricultural undertaking.

The growers selected will be required to meet the EU rules on how to grow medical cannabis whose quality is consistent.

Medical marijuana will not be a bonanza for all who wish to use it. Physicians will only prescribe it if a patient hasn’t benefited from all the available pain treatments in the country. Of special interest will be people suffering from cancer, multiple sclerosis, some forms of epilepsy and patients undergoing palliative care.

When addressing the French Senate at the beginning of the debate on the medical marijuana bill, Senator Esther Benbassa revealed that the list of conditions for which medical marijuana could be prescribed is likely to be expanded in future to include more ailments.

Some senators, especially those from the Republican Party, fear that the medical marijuana program is being used as a Trojan horse in a bid to legalize recreational marijuana. Advocates disagree and assert that medical marijuana cannot be abused for recreational purposes since the two uses require different forms of cannabis. For example, the advocates say that therapeutic-grade marijuana is low in THC, so recreational users cannot get the psychoactive effects which they require to address their needs.

Marijuana advocates welcomed the new bill and hope that the way will be opened for exploring other purposes for which marijuana can be used. These include wellness products like supplements, oils and cannabis-infused vitamins.

Marijuana Company of America Inc. (OTCQB: MCOA) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) welcome France into the fold of countries which are benefiting from the medicinal effects of marijuana.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Disruptive CBD Delivery Technology Could Revolutionize World of Cannabis Consumer Products, Edibles

CannabisNewsWire Editorial Coverage: Fueled by an explosion of CBD-infused edibles, billion-dollar projections for the CBD market may even be conservative.

This seems possible when one considers the truly innovative work being done in the sector by the likes of Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile), which has developed a patented delivery technology with disruptive potential, delivering 475% more CBD to the bloodstream after 15 minutes than conventional formulations. Other sector innovators are making a similar impact, including the likes of noted cannabinoid biopharma GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF) and that of researchers and product developers…

Read More >>

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

420 with CNW – Canopy Rivers Invests in New Zealand Agri-Tech Company

Canopy Rivers, one of the largest growers and suppliers of medical marijuana in the world, has invested $1.5 million in BioLumic, an agri-tech company based in New Zealand. The funds are intended to help the agri-tech company to develop UV treatments which can boost the performance and yield of marijuana plants.

Warren Bebb, the CEO of BioLumic, said that he was glad that companies from around the world were starting to pick interest in what his company is doing. Bebb attributes this interest to the results which they have already obtained for other flowering plants, such as tomatoes, soybeans, lettuce and strawberries.

The New Zealand parliament recently passed a law to give terminally ill patients a legal defense to possess and use cannabis (an illegal substance). This amendment has paved the way for companies with interests in medical cannabis to position themselves to get a share of the global medical cannabis industry which is predicted to grow to an $80 billion industry within the coming five years.

BioLumic is excited to take a shot at making a difference in the life of someone suffering from a terminal illness. The UV treatments developed by the company have already shown that performance and yield can increase by up to 40 percent. Test crops have been grown in various countries, such as Spain, Britain and Mexico.

Dr. Wargent, one of the co-founders at BioLumic, says that his company is unique because of the shorter time they need to treat plants. For example, they need just a week or two to treat seedlings and only a few minutes to treat seeds.

Once the scientists have treated the seeds or seedlings, no other treatment is required for the rest of the life of that plant.

Wargent, a photobiologist, explains that he started out by testing his revolutionary technology on just a few plants that he left within his bedroom. Last year, he and Bebb opened a state-of-the-art UV research and development facility at Massey University.

While the founders weren’t sure which exact direction their company would take, they were in agreement that it should become a unicorn (a start-up which grows to be worth at least $1 billion).

The investment by Canopy Rivers and other entities has helped BioLumic to get its journey to unicorn status underway. The funding from Canopy Rivers will also go towards expanding the Artificial Intelligence program of BioLumic in addition to upgrading security at their trial facilities around the world.

Marijuana Company of America Inc. (OTCQB: MCOA) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) congratulate BioLumic upon landing such a major client in the cannabis industry and hope that their partnership results in a method to take medical marijuana production to a new level of efficiency.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – China Reaps from Cannabis Industry Boom

Look around your home and nearly half (or even more) of the products you see may have been made in China. Now China has jumped into the fray and it is bringing loads of CBD to the market in cosmetics, ingestible oil and other products.

This boom is largely centered in just two of China’s 34 provinces. These provinces are cultivating the plants even if Chinese law is very strict on psychotropic drugs, with death sentences routinely handed out to drug traffickers.

Hanma Investment Group is one of the first companies that secured a license to grow cannabis in Southern China in 2017. The CBD extracted is marketed outside China in balms, oils and sprays.

Hanma Investment Group has a subsidiary that is cultivating industrial hemp on more than 1,600 acres in Yunnan Province.

For thousands of years, hemp and marijuana were widely grown across China for making ropes, fabrics, paper and for medicinal purposes until the People’s Republic of China was founded and clamped down on the plant in 1949.

Hemp was also outlawed in 1985 when China signed the UN Convention on Psychotropic Substances despite hemp having just trace amounts of THC.

It is only recently (2010) that China softened its stance and allowed Yunnan province to resume growing hemp for textiles, especially for making uniforms for the People’s Liberation Army.

The exploding interest in CBD around the world has made Yunna Province to add oil extraction to the growing list of products for which hemp is grown. This booming industry has breathed new life into the economy of Yunna since farmers can earn much more from growing hemp ($300 from an acre) when compared to growing other crops, such as rapeseed or flax.

Yunna Province now has four companies that have, in total, opened more than 36,000 acres of land for hemp cultivation.

The other province which is reaping from hemp is Heilongjiang Province. Other provinces are catching on and plans are underway to license companies to start growing hemp in more regions of China.

The announcements that different companies have started growing hemp have caused such a stir on the stock exchanges that regulators were forced to intervene and stop trading in the shares of those companies.

Chinese companies are also aggressively staking their claim on the U.S. hemp landscape. For example, Hanma Investment Group has acquired a CBD extraction plant in Las Vegas, Nevada, and it has also set its eyes on Canada as well.

The 2018 Farm Act removed hemp from the list of controlled substances and it is now an agricultural commodity like any other within the U.S. The onus is now on U.S. companies to take full advantage of this legal reform so that China doesn’t muscle out local players in the CBD industry. Marijuana Company of America Inc. (OTCQB: MCOA) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) hope that U.S. companies are up to the challenge so that foreign firms don’t dominate the local CBD market.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – Trump Administration Opposed to Medical Cannabis for Military Veterans

The Department of Veterans Affairs has voiced its opposition to three bills that are intended to protect the VA benefits of veterans who use medical cannabis in states where it is legal, allow VA doctors to prescribe medical cannabis in states where it is legal and also expand research into the medical potential of cannabis.

The VA officials were speaking during a congressional hearing on Tuesday (April 30). For example, Keita Franklin (suicide prevention national director in the VA department) was of the view that the bill compelling the VA department to conduct research on the medical benefits and risks of cannabis was “too ambitious and risky” because a large number of human subjects would be involved.

Franklin also cited the guidance provided by the Drug Enforcement Administration to the effect that VA medical personnel aren’t allowed to prescribe medical marijuana in states where medical marijuana is legal.

Furthermore, the VA officials explained that they are also opposed to the bill which seeks to protect the VA benefits of veterans who consume medical cannabis in states where it is legal because the department already has a policy to that effect.

However, the sponsor of the bill insisted that the policy referred to isn’t sufficient since another administration can decide to reverse it. The best option is to write those protections into law, the lawmakers argued.

Several military veterans’ advocacy groups were also represented and expressed strong support for all the bills. The groups included Disabled American Veterans, Veterans of Foreign Wars and Iraq and Afghanistan Veterans of America.

The strongest support among these advocacy groups was directed towards the bill seeking for more research into the therapeutic effects of marijuana.

The Veterans of Foreign Wars was however concerned that the VA wouldn’t be able to avail medical cannabis at its health facilities even if a policy shift occurred to permit doctors to prescribe medical marijuana. For this reason, the group wasn’t in support of the bill that intends to allow VA doctors to prescribe cannabis.

Some lawmakers were frustrated by the continuous stonewalling exhibited by the VA each time marijuana is up for discussion. The lawmakers suggested that it may be necessary to push for cannabis rescheduling since any bill that is passed will need the approval of the DEA, and the same response (rejection) will be given.

Marijuana Company of America Inc. (OTCQB: MCOA) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) can’t wait for the day when the debate on medical marijuana will focus on facts and the needs of the intended beneficiaries rather than on politics.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – American Cannabis Sales Expected to Double on 4/20

For the uninitiated, 4/20 in the marijuana industry can be equated to Fourth of July. The exact origin of that “holiday” isn’t known, but there is speculation that the day is named after the time of the day (4:20 p.m.) when a group of students would meet outside their high school in the 1970s to hunt for some legendary cannabis plants that had been abandoned. According to that myth, those students never found that marijuana crop, so they doggedly kept up their search.

On 4/20, sales of marijuana are expected to, at the very least, double at all retail facilities in the U.S. states where recreational cannabis is legal.

This projection is drawn from the data collected by Headset Inc. The statistics show that historically, 4/20 has been the busiest day for pot sellers. This is especially true when that date falls on a Friday.

According to Headset Inc., 4/20 last year saw a 111 percent jump in sales when the sales on that day were compared to the cannabis sales on four Fridays before that day and another four after the “holiday.” The data analyzed was taken from Washington State, Nevada, Colorado and California.

In comparison, beer sales registered a modest jump in the two weeks that included July 4. Only a 33 percent rise in sales was discovered when the number crunchers did the math. This shows that cannabis “holidays” draw a more enthusiastic weed buyer response when compared to the way beer consumers behave on July 4.

Another way to see it would be that the trajectory of cannabis sales is on a sharp rise while beer sales reached their peak long ago, so holidays cannot trigger major movements in the market.

As already indicated, last year’s 4/20 fell on a Friday, a day when cannabis consumers seem to visit retail outlets more. This year’s 4/20 will be on Saturday, so that brings even better news to recreational cannabis retailers since the “eve” of 4/20 will be a magnet to buyers and the “holiday” itself will also inspire cannabis consumers to spend on weed. Chances are therefore high that marijuana sales will be record-breaking during that long Easter weekend.

The cannabis crowd across the border in Canada will not enjoy the day as much as their American counterparts will. This is because any added demand for recreational cannabis in Canada will be dampened by the persistent supply shortages that have refused to go away since weed was legalized on October 17, 2018.

Queues will be longer on that day, especially in places like Toronto where retail facilities are limited. And unfortunately, not all who line up will leave a retail store with their first-choice cannabis product. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Marijuana Company of America (OTCQB: MCOA) look forward to the day when there will be no more cannabis shortages in Canada so that the people there can access all the products that they want.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – Student-Organized Event Discusses Cannabis on Sidelines of Michigan Hash Bash

Every year, a Hash Bash festival is held in Ann Arbor as a day of having fun and entertainment. This year, law students at Michigan Law School worked with the organizers of the Hash Bash festival to host an event at the law school to discuss marijuana legalization politics.

This event was held yesterday (Sunday, April 7) while the Hash Bash took place on Saturday. The organizers of the event at Michigan Law School wanted to educate members of the public about issues related to marijuana. Several panelists made presentations on various issues.

Ari Goldstein, a law student who was one of the organizers, remarked that marijuana legalization brings entrepreneurial opportunities that haven’t been seen since the Great Depression, so every effort must be taken to prepare people to seize those opportunities.

Kevin Boehnke, who is a research fellow at Michigan University’s Department of Anesthesiology, revealed during his presentation that several patient studies point to the fact that more patients are opting for medical marijuana to manage pain instead of using prescription opioids.

The shift is due to the better symptom relief experienced by patients, and the concerns about the documented side effects of prescription opioids.

Another panelist, Gus Rosania (a professor of pharmacological sciences) handled the topic of natural vs. synthetic cannabis ingredients. Rosania dispelled the misconception that synthetic cannabis is different from natural cannabis.

He revealed that at the basic level, synthetic marijuana is chemically identical to natural marijuana, so it is hard to tell the two apart. He added that it was only because different ingredients could be isolated and made in a lab that it was possible to identify the different cannabinoids in marijuana.

Andrew Brisbo, the head of Michigan’s Bureau of Marijuana Regulation, was also in attendance to talk about the ramifications of the legalization of recreational cannabis in the state. He revealed that he had a huge task on his desk to put together a program for recreational cannabis implementation in just a year from the time the law was passed.

Brisbo intimated that one way that he was using to get everything done correctly is by engaging different stakeholders in order to tap their perspectives when putting together an implementation plan.

Many people in the audience expressed their frustration about how hard it was for them to get a medical cannabis prescription from their doctors. Brisbo expressed sympathy for their plight and revealed that it wasn’t easy to change attitudes about cannabis after such a long time of prohibition. He added that efforts were underway to give physicians more information about medical cannabis so that they can gradually warm up to prescribing it to their patients who qualify for such treatment.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Marijuana Company of America, Inc. (OTCQB: MCOA) welcome such engagements between regulators, patients, professors and other stakeholders since such interactions can result in better cannabis industry policies.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – New York Cannabis Legalization Process Hits Major Snag

The process of legalizing recreational marijuana in New York has hit a major snag with the announcement that it isn’t included in the state budget for 2020. This means that it may now be harder to pass the legalization bill as a standalone bill.

Gov. Andrew Cuomo (D) has been pushing to have the bill included in the state budget for 2020, but it seems things haven’t gone his way.

The major issue in the way of legalization appears to be disagreements regarding how the program will be implemented. For example, the legislators are sharply divided about the way in which the taxes from recreational weed should be spent.

Another source of disagreement is the insistence by people of color that measures should be included in the law to avail economic opportunities in the industry to the racial groups, such as African Americans, which suffered the most during the war on drugs. Expunging criminal records isn’t enough, they say.

Even Cuomo admits that the task of passing the bill will be harder now that it isn’t included in the budget. However, the Governor is still optimistic that discussions on legalization will continue at a slower pace and a law may be in place this year.

Before this setback, many legislators had expressed reservations about the possibility of reaching a consensus in time to include marijuana legalization in the budget. Their fears just materialized, and cannabis legalization just got a little harder to attain.

The setback in New York State comes just days before neighboring New Jersey was expected to vote on a bill that would legalize recreational pot. However, that vote was called off on Monday (March 25), to the disappointment of marijuana advocates.

The New Jersey vote cancellation was a strategic decision by the Governor, the State Senate leader and the head of the Assembly. They opted to delay the vote so that they work to secure sufficient support for the bill, rather than insisting that the vote happens and the bill fails to get enough support.

You can now see how the situation in New York State is similar to what happened in New Jersey. Both processes have slowed or stalled because of insufficient support or disagreements among legislators despite the overwhelming public support for legalization.

Green Hygienics Holdings Inc. (OTCQB: GRYN) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) urge the legislators in New York State to listen to each other and reach a compromise for the good of the people in the state.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com